F. Hoffmann-La Roche AG said on Thursday its annual sales in 2024 reached 60.5 billion Swiss francs, climbing 3% in Swiss francs and 7% at constant exchange rates (CER) from the same period a year earlier. Sales in the pharmaceuticals division grew 8% at CER to 46.2 billion Swiss francs, while diagnostics division sales rose 4% at CER year on year to 14.3 billion Swiss francs.
In the year, net income dropped 19% at CER to 9.2 billion Swiss francs while diluted EPS fell 20% to 10.31 Swiss francs. For 2025, the pharmaceutical firm "expects an increase in Group sales in the mid-single-digit range (CER). Core earnings per share are targeted to develop in the high single-digit range (CER)," the report showed.
"Core earnings per share exceeded the guidance raised at half year … Roche is well positioned for future growth," CEO Thomas Schinecker stated.
